Published in Vaccine Weekly, June 24th, 2009
"BD Biosciences is committed to addressing the needs of pharmaceutical researchers," said Charles Crespi, Ph.D., Vice President of Discovery Biologicals, BD Biosciences. "This new reagent will allow scientists to maintain consistent, high-quality results in their assays and avoid the arduous task of qualifying new lots of reagents."
Cytochromes P450 (CYPs) are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2009-06-24)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.